Photodynamic Therapy: a New Approach to Prostate Cancer

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2003 May 21

PMID 12756086

Citations 8

Authors

Rolf Muschter

Affiliations

Soon will be listed here.

Abstract

Photodynamic therapy (PDT) is based on the concept that light irradiation can change an inert substance into an active one. In urology, hematoporphyrin derivative (HpD) and Photofrin (Axcan Scandipharm Inc., Birmingham, AL) are used most commonly as photosensitizing agents predominantly for the treatment of transitional cell carcinoma of the bladder. To investigate the basics for PDT of prostate cancer, several studies were performed on the optical characteristics of prostate tissue and prostate carcinoma tissue in vitro and in vivo and on the penetration depths of different laser wavelengths. Initial experimental studies to treat prostate cancer with PDT using HpD were done on Dunning tumors in rats. Combined with interstitial applicators, photodynamic therapy seems to have a great potential in the treatment of prostate carcinoma. However, it is an experimental treatment and even a preliminary evaluation will be possible only after the conclusion of clinical studies with the corresponding long-term results.

Citing Articles

Polymer theranostics with multiple stimuli-based activation of photodynamic therapy and tumor imaging.

Tavares M, Islam R, Subr V, Hackbarth S, Gao S, Yang K Theranostics. 2023; 13(14):4952-4973.

PMID: 37771769 PMC: 10526675. DOI: 10.7150/thno.86211.

Polymeric nanocarrier systems for photodynamic therapy.

Li L, Huh K Biomater Res. 2015; 18:19.

PMID: 26331070 PMC: 4552462. DOI: 10.1186/2055-7124-18-19.

Towards recombinant antibody-fragment targeted photodynamic therapy.

Milgrom L Sci Prog. 2008; 91(Pt 3):241-63.

PMID: 18853576 PMC: 10367486. DOI: 10.3184/003685008X361415.

Treatment planning using tailored and standard cylindrical light diffusers for photodynamic therapy of the prostate.

Rendon A, Beck J, Lilge L Phys Med Biol. 2008; 53(4):1131-49.

PMID: 18263963 PMC: 2649773. DOI: 10.1088/0031-9155/53/4/021.

The effect of Tookad-mediated photodynamic ablation of the prostate gland on adjacent tissues--in vivo study in a canine model.

Huang Z, Chen Q, Dole K, Barqawi A, Chen Y, Blanc D Photochem Photobiol Sci. 2007; 6(12):1318-24.

PMID: 18046488 PMC: 2302792. DOI: 10.1039/b705984a.

References

Chang S, Buonaccorsi G, MacRobert A, Bown S . Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX. Prostate. 1997; 32(2):89-98. DOI: 10.1002/(sici)1097-0045(19970701)32:2<89::aid-pros3>3.0.co;2-a. View

Jocham D, Baumgartner R, Stepp H, Unsold E . Clinical experience with the integral photodynamic therapy of bladder carcinoma. J Photochem Photobiol B. 1990; 6(1-2):183-7. DOI: 10.1016/1011-1344(90)85088-e. View

Chang S, Buonaccorsi G, Macrobert A, Bown S . Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin. Int J Cancer. 1996; 67(4):555-62. DOI: 10.1002/(SICI)1097-0215(19960807)67:4<555::AID-IJC15>3.0.CO;2-6. View

Benson Jr R, Kinsey J, Cortese D, Farrow G, Utz D . Treatment of transitional cell carcinoma of the bladder with hematoporphyrin derivative phototherapy. J Urol. 1983; 130(6):1090-5. DOI: 10.1016/s0022-5347(17)51699-7. View

Momma T, Hamblin M, Wu H, Hasan T . Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res. 1998; 58(23):5425-31. View

Benson Jr R, Farrow G, Kinsey J, Cortese D, Zincke H, Utz D . Detection and localization of In situ carcinoma of the bladder with hematoporphyrin derivative. Mayo Clin Proc. 1982; 57(9):548-55. View

Gonzalez S, Arnfield M, Meeker B, Tulip J, LAKEY W, Chapman J . Treatment of Dunning R3327-AT rat prostate tumors with photodynamic therapy in combination with misonidazole. Cancer Res. 1986; 46(6):2858-62. View

Arnfield M, Chapman J, Tulip J, Fenning M, McPhee M . Optical properties of experimental prostate tumors in vivo. Photochem Photobiol. 1993; 57(2):306-11. DOI: 10.1111/j.1751-1097.1993.tb02292.x. View

Shumaker B, Hetzel F . Clinical laser photodynamic therapy in the treatment of bladder carcinoma. Photochem Photobiol. 1987; 46(5):899-901. DOI: 10.1111/j.1751-1097.1987.tb04866.x. View

10.

Selman S, Albrecht D, Keck R, Brennan P, Kondo S . Studies of tin ethyl etiopurpurin photodynamic therapy of the canine prostate. J Urol. 2001; 165(5):1795-801. View

11.

Nathan T, Whitelaw D, Chang S, Lees W, Ripley P, Payne H . Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol. 2002; 168(4 Pt 1):1427-32. DOI: 10.1016/S0022-5347(05)64466-7. View

12.

Chen Q, Huang Z, Luck D, Beckers J, Brun P, Wilson B . Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers. Photochem Photobiol. 2002; 76(4):438-45. DOI: 10.1562/0031-8655(2002)076<0438:PSINCP>2.0.CO;2. View

13.

Lee L, Whitehurst C, Chen Q, Pantelides M, Hetzel F, Moore J . Interstitial photodynamic therapy in the canine prostate. Br J Urol. 1998; 80(6):898-902. DOI: 10.1046/j.1464-410x.1997.00460.x. View

14.

Bedwell J, MacRobert A, Phillips D, Bown S . Fluorescence distribution and photodynamic effect of ALA-induced PP IX in the DMH rat colonic tumour model. Br J Cancer. 1992; 65(6):818-24. PMC: 1977757. DOI: 10.1038/bjc.1992.175. View

15.

Kelly J, Snell M, BERENBAUM M . Photodynamic destruction of human bladder carcinoma. Br J Cancer. 1975; 31(2):237-44. PMC: 2009375. DOI: 10.1038/bjc.1975.30. View

16.

Colasanti A, Kisslinger A, Liuzzi R, Quarto M, Riccio P, Roberti G . Hypericin photosensitization of tumor and metastatic cell lines of human prostate. J Photochem Photobiol B. 2000; 54(2-3):103-7. DOI: 10.1016/s1011-1344(99)00149-9. View

17.

Windahl T, Andersson S, Lofgren L . Photodynamic therapy of localised prostatic cancer. Lancet. 1990; 336(8723):1139. DOI: 10.1016/0140-6736(90)92626-s. View

18.

Xue L, Qiu Y, He J, Kung H, Oleinick N . Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin. Oncogene. 1999; 18(22):3391-8. DOI: 10.1038/sj.onc.1202687. View

19.

Whitehurst C, Pantelides M, Moore J, Brooman P, Blacklock N . In vivo laser light distribution in human prostatic carcinoma. J Urol. 1994; 151(5):1411-5. DOI: 10.1016/s0022-5347(17)35270-9. View

20.

Chen Q, Hetzel F . Laser dosimetry studies in the prostate. J Clin Laser Med Surg. 1998; 16(1):9-12. DOI: 10.1089/clm.1998.16.9. View